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Review
Although Italy lacks a national rare donor program, there 
are several local and two regional rare donor programs in the 
country. The first regional program, the Lombardy Rare Donor 
Programme (LORD-P), was established in 2005 in Lombardy, 
a region with an ethnically varied population of approximately 
9.8 million inhabitants that includes 250,000 blood donors. 
In 2010, another rare donor program was established at the 
Blood Transfusion Center of Ragusa Hospital in Sicily; this 
program has typed 12,444 blood donors, of which 150 were 
negative for high-prevalence antigens [98 k–, 26 Fy(a–b–), 3 
Co(a–), 11 Lu(b–), 1 Jo(a–), 1 Di(b–), 1 Js(b–), 9 Yt(a–)].
LORD-P was established through the collaboration of 
15 regional blood transfusion departments and with the 
support of a regional government grant. During 2005 to 
2014, the Lombardy Region supported LORD-P with €1.3 
million per year. The LORD-P and blood bank of fresh and 
frozen rare red blood cell (RBC) units were established at the 
Blood Transfusion Centre, Foundation Ca' Granda Ospedale 
Maggiore Policlinico, in Milan under the coordination of the 
Immunohematology Reference Laboratory (IRL), which has 
been accredited as an IRL by the AABB since 2003. Each of 
the 15 regional blood transfusion departments selects blood 
donors aged 18–55 years (including Caucasians and ethnic 
minorities) with a history of two or more blood donations and 
sends a small blood sample for extensive typing to the IRL. 
From 2005 to June 2009, an automated, high-throughput 
system (Galileo, Immucor, Norcross, GA) was used for the 
serological typing of groups A and O blood donors, selected by 
Rh phenotype (CCDee [R1R1], ccdee [rr], ccDEE [R2R2], ccDee 
[R0R0]) and being negative for K or k. The panel tested for Fya, 
Fyb; Jka, Jkb; S, s; Coa; Jsb; Ge2; Lub; Kpb; PP1Pk; U; Vel; and Yta. 
Until December 2006, antigen-negative status was confirmed 
serologically using different antisera by Galileo or by manual 
tube testing. Beginning in January 2007, all confirmatory 
typing was performed by molecular methods using a local 
procedure incorporating Luminex technology (Luminex Corp., 
Austin, TX) or by commercial polymerase chain reactions with 
sequence-specific primers (Inno-Train Diagnostik, Kronberg, 
Taunus, Germany). Starting in June 2009, a high-throughput 
genotyping method based on DNA microarray technology, 
the HEA BeadChip kit (BioArray Solutions, Immucor), was 
used to increase the number of typed RBC alleles. The HEA 
kit performs multiple assays on one sample and analyzes 
38 polymorphisms associated with 11 blood group systems 
including RH, KEL, JK, FY, MNS, LU, DI, CO, DO, LW, and SC.
From 2005 to 2014, the program yielded 10,040 active 
donors who were rare for a combination of common antigens, 
579 who were negative for high-prevalence antigens, and 48 
with a rare Rh phenotype. In 2012–2014, a total of 2492 new 
rare donors were added. Of these, 177 were rare for high-
prevalence antigens or Rh phenotype. In December 2014, the 
LORD-P registry included the clinically relevant phenotypes 
shown in Table 1.
Although originally established to meet the needs of 
patients treated in Lombardy, the LORD-P registry and 
blood bank of frozen RBC units has contributed to resolving 
planned and urgent transfusion needs of complex immunized 
transfusion candidates throughout the country.
In 2012–2014, a total of 1058 requests for rare blood units 
were referred to LORD-P registry and 1595 rare units were 
issued. Of these, 450 were rare for high-prevalence antigens or 
rare for Rh phenotype, as shown in Table 2.
During 2012–2014, all requests for compatible units were 
filled, with the exception of one request for Gy(a–) units for 
delivery in a pregnant woman with anti-Gya. A 33-year-old 
Table 1. Donors in rare donor program in Italy (2005–2014)
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woman at 25 weeks’ gestation was referred to our hospital 
because her antibody screen was positive by an indirect 
antiglobulin test (IAT) with all cells tested. We detected anti-
Gya with a very low titer (1) by the IAT. The prevalence of 
Gy(a–) is known to be extremely rare, and only four donors 
were available in the International Rare Donor Panel. At 40 
weeks’ gestation, a baby was delivered by caesarean section, 
but no units were available. For this reason, IgG prophylaxis 
was recommended, but during the delivery, RBC units were 
not necessary. The infant suffered neither from anemia nor 
from severe jaundice.
Incompatible Transfusion Cases
No reports of acute or delayed hemolytic transfusion 
reactions were received by the IRL after the transfusion 
of shipped rare RBC units, although we are aware of the 
possibility of inaccurate or incomplete reporting of adverse 
events and transfusion reactions.
Incentives for Rare Donors
Despite the increase in blood usage and the critical 
seasonal blood shortages, the national blood service is based 
on voluntary non-remunerated blood donations. In fact, 
donors do not receive any cash incentives but may be given 
the day off from work on the day of donation. Furthermore, 
donors may be enrolled in preventive medicine programs 
offered by the blood center.
Rhnull Donors
As reported in the literature,1,2 the Rhnull phenotype is 
extremely rare and is associated with two distinct molecular 
backgrounds: the amorph type results from inactivating 
mutations in RHCE and a deletion of RHD, whereas the regular 
type results from homozygosity for inactivating mutations in 
RHAG. According to the results of a survey by the International 
Society of Blood Transfusion Rare Donor Working Party in 
Amsterdam in 2013, no Rhnull donor has been identified in 
Italy.
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Table 2. Rare units issued in 2012–2014
Antigen/phenotype Number of units
Yt(a–) 153
k– 122
Fy(a–b–) 74
Lu(b–) 74
CCdee (r′r′) 13
CCDEE (RzRz) 5
Js(b–) 4
ccdEE (r″r″) 3
U– 2
Total 450
